AR080865A1 - Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. - Google Patents

Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.

Info

Publication number
AR080865A1
AR080865A1 ARP110101073A ARP110101073A AR080865A1 AR 080865 A1 AR080865 A1 AR 080865A1 AR P110101073 A ARP110101073 A AR P110101073A AR P110101073 A ARP110101073 A AR P110101073A AR 080865 A1 AR080865 A1 AR 080865A1
Authority
AR
Argentina
Prior art keywords
alkyl
acyl
alkoxy
heterocycle
carbocycle
Prior art date
Application number
ARP110101073A
Other languages
English (en)
Inventor
Adam Cook
Indrani W Gunawardana
Kevin W Hunt
Nicholas Kallan
Michael Siu
Allen A Thomas
Christopher T Clark
Mathew Volgraf
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of AR080865A1 publication Critical patent/AR080865A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C07D263/64—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Reivindicacion 1: Un compuesto seleccionado desde la formula (1) y esteroisomeros, diaesteroisomeros, enantiomeros, tautomeros y sales farmacéuticamente aceptables de los mismos caracterizados porque W es un enlace o CR10R11; Y es O, S o NR1; Z es CR12R13 o C(=O), proporcionado cuando Z es C(=O) entonces Y es NR1; X1, X2 y X3 se seleccionan independientemente desde CR9 y N, caracterizado porque solamente uno de X1, X2 o X3 puede ser N; R1 se selecciona desde hidrogeno, alquilo, aralquilo, heteroarilo o heteroaralquilo; R2 se selecciona desde hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo, ariloxi, un carbociclo o un heterociclo caracterizado porque dicho alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo, ariloxi, carbociclo y heterociclo se sustituyen opcionalmente con hidroxi, halogeno, amino, ciano, nitro, oxo, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, sulfanilo, acilo, alcoxicarbonilo, haloalquilo, carbociclo opcionalmente sustituido o heterociclo; R3 y R4 se seleccionan independientemente desde hidrogeno, halogeno y alquilo, o R3 y R4 juntos forman un grupo oxo; R5 y R6 son independientemente hidrogeno, hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo, un carbociclo o un heterociclo caracterizado porque, dicho alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo, carbociclo y heterociclo se sustituyen opcionalmente con hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo, haloalquilo, un carbociclo opcionalmente sustituido y un heterociclo opcionalmente sustituido, o R5 y R6 juntos forman un carbociclo de 3 a 6 miembros o un heterociclo opcionalmente sustituido con hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo y haloalquilo; R7 y R8 son independientemente hidrogeno, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo, un carbociclo o un heterociclo caracterizado porque dicho alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo carbociclo y heterociclo se sustituyen opcionalmente con hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo, haloalquilo, un carbociclo y un heterociclo opcionalmente sustituido, o R7 y R8 juntos forman un carbociclo de 3 a 6 miembros o un heterociclo opcionalmente sustituido por hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo y haloalquilo; R9 es independientemente hidrogeno, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo, un carbociclo o un heterociclo caracterizado porque dicho alquilo, alcoxi, acilo, aciloxi, alcoxicarbonilo, sulfonilo, sulfinilo, sulfanilo, carbociclo y heterociclo se sustituyen opcionalmente con hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo y haloalquilo, o R5 y R7 juntos forman un carbociclo de 3 a 4 miembros o heterociclo opcionalmente sustituido por hidroxi, halogeno, amino, ciano, nitro, alquilo, alcoxi, acilo y haloalquilo; cada R9 se selecciona independientemente del hidrogeno, halogeno o metilo; R10 y R11 se seleccionan independientemente desde hidrogeno y alquilo, o R10 y R11 juntos forman el átomo al cual se unen para formar un carbociclo de 3 a 6 miembros o un heterociclo; y R12 y R13 se seleccionan independientemente desde hidrogeno, alquilo y un carbociclo.
ARP110101073A 2010-03-31 2011-03-31 Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. AR080865A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31934110P 2010-03-31 2010-03-31
US201161439723P 2011-02-04 2011-02-04

Publications (1)

Publication Number Publication Date
AR080865A1 true AR080865A1 (es) 2012-05-16

Family

ID=43927953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101073A AR080865A1 (es) 2010-03-31 2011-03-31 Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.

Country Status (3)

Country Link
US (1) US20120065195A1 (es)
AR (1) AR080865A1 (es)
WO (1) WO2011123674A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
MX2014002113A (es) 2011-08-22 2014-04-25 Merck Sharp & Dohme Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
JP2014526560A (ja) 2011-09-21 2014-10-06 アムジエン・インコーポレーテツド β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
WO2013148851A1 (en) * 2012-03-27 2013-10-03 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
CA2873678A1 (en) 2012-05-30 2013-12-05 Comentis, Inc. Chromane compounds
EP2669286A1 (en) * 2012-05-31 2013-12-04 Ares Trading S.A. Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
WO2014052398A1 (en) 2012-09-28 2014-04-03 Vitae Pharmaceuticals, Inc. Inhibitor of beta-secretase
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014099788A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
CN115322208B (zh) * 2021-05-10 2023-04-11 中国药科大学 2-氨基噻唑类衍生物及其制备方法和医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP0975608B1 (en) 1997-04-15 2005-06-15 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
AU2008277676A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as MK2 inhibitors
WO2010021680A2 (en) * 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase

Also Published As

Publication number Publication date
WO2011123674A1 (en) 2011-10-06
US20120065195A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
TR201810944T4 (tr) Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
NI201400108A (es) Compuestos de heterociclilo
CR20150045A (es) Inhibidores de hepatitis c
CO2017000438A2 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
RS54288B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS
EA201591195A1 (ru) Новые хинолоновые производные
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
AR085987A1 (es) Compuestos tri- y tetraciclicos pirazol[3,4-b]piridina como agentes antineoplasicos
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR063805A1 (es) Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas.
CY1121147T1 (el) Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου
ECSP088257A (es) Derivados de amida
AR061185A1 (es) Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
AR111826A1 (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
EA201692090A1 (ru) Полициклические активаторы herg
UY35945A (es) Derivados de azaindol

Legal Events

Date Code Title Description
FB Suspension of granting procedure